1260-Prostate Cancer: Genomic Landscape & Precision Therapy

This paper provides a comprehensive analysis of the genomic landscape and precision medicine strategies currently reshaping prostate cancer management. The text highlights how molecular profiling has identified critical drivers of disease progression, such as androgen receptor signaling, DNA damage repair mutations, and lineage plasticity. These biological insights are enabling the transition from standardized treatments to individualized therapies, including PARP inhibitors, radioligand treatments, and immune checkpoint blockades. Despite these clinical improvements, the authors emphasize that genomic heterogeneity and treatment resistance remain significant hurdles to achieving optimal patient outcomes. The review ultimately advocates for continued innovation in biomarker-driven diagnostics to address racial disparities and refine personalized care for advanced disease stages.

References:

• Ligon J A, Anand S, Singh S, et al. Genomic landscape and precision therapy in prostate cancer: current status and future directions[J]. npj Precision Oncology, 2026.